Navigation Links
Oncothyreon Reports Third Quarter 2010 Financial Results
Date:11/8/2010

ment activities for ONT-10, as well as the legal, accounting and consulting expenses associated with regulatory compliance in the first quarter of 2010.  Oncothyreon currently expects cash used in operations in 2010 to be approximately $18-19 million. As a result, Oncothyreon estimates that its existing cash will be sufficient to fund operations for at least the next 12 months. Conference Call Details Oncothyreon will conduct a conference call to discuss its third quarter 2010 financial results and provide a review of its pipeline of products in development today at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).  To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International).  In addition, the call will be webcast live and can be accessed on the "Events" page of the "News & Events" section of Oncothyreon's website at href="http://www.oncothyreon.com/">www.oncothyreon.com.  An archive of the webcast will be available after completion of the discussion and will be posted on the Oncothyreon website. About Oncothyreon Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.  For more information, visit www.oncothyreon.com. Forward-Looking Statements In order to provide Oncothyreon's investors with an understanding of our current results and future prospects, this release may contain statements that are forward-looking.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "po
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
2. Oncothyreon announces prioritization plan for development programs
3. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
4. Oncothyreon to present at BIO Investor Forum 2008
5. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
6. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
7. Oncothyreon reports third quarter 2008 financial results
8. Oncothyreon to present at BIO CEO & Investor Conference 2009
9. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
10. Oncothyreon reports full year and fourth quarter 2008 financial results
11. Oncothyreon to present at Invest Northwest 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... the Institute for Molecular Medicine Finland (FIMM), University ... a novel "man and machine" decision support system ... was described in PLOS One scientific ... on computer vision algorithms similar to those used ... only the diagnostically most relevant areas. Tablet computers ...
(Date:8/21/2014)... , August 21, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... hormone therapy, is a means of replacing ... by the body. This type of therapy ...
(Date:8/21/2014)... 2014 The College of New Rochelle ... in the Mid-Hudson Region to be designated as a ... applications from qualified “high-technology” businesses that align with the ... to have been selected for the START-UP NY program ... to stimulate economic development in New York by growing ...
(Date:8/21/2014)... YORK , Aug. 21, 2014 ... congratulates Immune Pharmaceuticals Inc., a biotechnology company, on ... Market.  Immune previously traded on OTCQX®, the best ... by OTC Markets Group. Logo - ... Pharmaceuticals on the successful execution of its growth ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... Sequence Analysis Problem -, - Exhibit to Spotlight ... MISSION VIEJO, Calif., Sept. 26 Supporting ... genomic search,technology, SLIM Search, Inc. announces it is ... Next Generation,Sequencing Conference. The conference will review new ...
... Phil Coggins to Continue as President and CSO, ... Osprey,Pharmaceuticals, Ltd., a privately held biotechnology company developing,first-in-class ... today the appointment of Jack M. Anthony to ... the position of,CEO will continue as President and ...
... September 26 XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ... September 24, 2007, the Company received a NASDAQ ... with the minimum,$10 million shareholders, equity requirement for ... forth in Marketplace Rule 4450(a)(3), and that,its ADRs ...
Cached Biology Technology:SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market 2SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market 3SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market 4Osprey Pharmaceuticals Names Jack M. Anthony as CEO 2Osprey Pharmaceuticals Names Jack M. Anthony as CEO 3XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 2XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 3
(Date:8/21/2014)... geologist Juliane Mller the Fram Strait is a key region ... this passage between Greenland and Svalbard warm Atlantic water flows ... west side cold Arctic water masses and sea ice push ... A considerable portion of the Atlantic water cools here on ... The circulation of the water caused in this manner drives ...
(Date:8/21/2014)... designed by an international standards process, will be available ... an invited review published in the OnlineFirst version of ... the official journal of the American Society for Parenteral ... reduce the occurrence of misconnection that can be harmful ... are used to join medical devices, components, and accessories ...
(Date:8/21/2014)... in severe abdominal pain, vomiting and systemic inflammation. Every ... with the disease resulting in 1000 deaths. There is ... fluid and nutritional support. , Dr Jason Bruce, ... research, said "The major causes of pancreatitis include bile ... combined with a high fat diet. In fact, the ...
Breaking Biology News(10 mins):Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3New feeding tube connectors will improve patient safety 2Insulin offers new hope for the treatment of acute pancreatitis 2
... Spanish . Making DNA sequences being passed through ... point that they take on the form of diminutive spaghetti. This ... of the lines of research in which CIC microGUNE is working, ... are shortly to apply for a patent. The technique basically consists ...
... New York / Heidelberg, 6 April 2011 The ... pads of many insects, lizards and spiders give them the ... James Bullock and Walter Federle from the University of Cambridge ... away these adhesive hairs from surfaces are what allows beetles ...
... used to rehabilitate the arms and hands of people who ... the University of Southampton. In a paper to be ... and Technology (IET) Assisted Living Conference, Dr Geoff Merrett, a ... and evaluation of three technologies which could help people who ...
Cached Biology News:DNA stretching -- A new technique being carried out at CIC microGUNE to detect illnesses 2Nature helps to solve a sticky problem 2Scientists develop new technology for stroke rehabilitation 2
Custom LNA Oligonucleotide synthesis ,High quality Custom LNA Oligonucleotides are available for a variety of different specialty applications and innovative products. ,Please inquire for further...
... Plus is a chemiluminescent signal enhancing ... to boost the signal obtained with ... kits. ChemiLucent™ Plus is derived from ... conjugated complex- or chemiluminescent substrate enhancers, ...
... Multi-Disciplinary Team The Schleicher & ... stand-alone work center dedicated to custom ... The facilitys experienced project teams, comprised ... Marketing professionals, work closely with collaborators ...
... microRNA (miRNA) expression profiling service using Paraflo ... highly sensitive and specific direct detection of ... mature miRNA of all species available in ... database (Release 8.2). Our service is comprehensive ...
Biology Products: